| Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients F Tovoli, L Ielasi, A Casadei-Gardini, A Granito, FG Foschi, G Rovesti, ... Journal of hepatology 71 (6), 1175-1183, 2019 | 70 | 2019 |
| Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives C Tomasello, C Baldessari, M Napolitano, G Orsi, G Grizzi, F Bertolini, ... Critical reviews in oncology/hematology 123, 149-161, 2018 | 62 | 2018 |
| Gastric cancer: translating novels concepts into clinical practice M Salati, G Orsi, E Smyth, G Beretta, F De Vita, M Di Bartolomeo, ... Cancer treatment reviews 79, 101889, 2019 | 61 | 2019 |
| Soluble TRAIL armed human MSC as gene therapy for pancreatic cancer C Spano, G Grisendi, G Golinelli, F Rossignoli, M Prapa, M Bestagno, ... Scientific reports 9 (1), 1788, 2019 | 61 | 2019 |
| Inducible Caspase9-mediated suicide gene for MSC-based cancer gene therapy F Rossignoli, G Grisendi, C Spano, G Golinelli, A Recchia, G Rovesti, ... Cancer Gene Therapy 26 (1), 11-16, 2019 | 53 | 2019 |
| MSC-delivered soluble TRAIL and paclitaxel as novel combinatory treatment for pancreatic adenocarcinoma F Rossignoli, C Spano, G Grisendi, EM Foppiani, G Golinelli, I Mastrolia, ... Theranostics 9 (2), 436, 2019 | 48 | 2019 |
| GD2 expression in breast cancer G Orsi, M Barbolini, G Ficarra, G Tazzioli, P Manni, T Petrachi, I Mastrolia, ... Oncotarget 8 (19), 31592, 2017 | 46 | 2017 |
| Impact of baseline characteristics on the overall survival of HCC patients treated with sorafenib: ten years of experience G Rovesti, G Orsi, A Kalliopi, C Vivaldi, G Marisi, L Faloppi, FG Foschi, ... Gastrointestinal Tumors 6 (3-4), 92-107, 2019 | 36 | 2019 |
| Lenvatinib as a therapy for unresectable hepatocellular carcinoma A Spallanzani, G Orsi, K Andrikou, F Gelsomino, M Rimini, L Riggi, ... Expert Review of Anticancer Therapy 18 (11), 1069-1076, 2018 | 34 | 2018 |
| ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib G Marisi, E Petracci, F Raimondi, L Faloppi, FG Foschi, G Lauletta, ... Cancers 11 (7), 1023, 2019 | 29 | 2019 |
| Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort U Peretti, A Cavaliere, M Niger, G Tortora, MC Di Marco, MG Rodriquenz, ... ESMO open 6 (1), 100032, 2021 | 23 | 2021 |
| EUS-guided gastroenterostomy for management of malignant gastric outlet obstruction: A prospective cohort study with matched comparison with enteral stenting G Vanella, G Dell’Anna, G Capurso, P Maisonneuve, M Bronswijk, ... Gastrointestinal Endoscopy 98 (3), 337-347. e5, 2023 | 21 | 2023 |
| Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants M Macchini, F Centonze, U Peretti, G Orsi, AM Militello, MM Valente, ... Cancer Treatment Reviews 100, 102262, 2021 | 21 | 2021 |
| Prognostic role of blood eosinophil count in patients with sorafenib-treated hepatocellular carcinoma G Orsi, F Tovoli, V Dadduzio, C Vivaldi, O Brunetti, L Ielasi, F Conti, ... Targeted Oncology 15, 773-785, 2020 | 17 | 2020 |
| Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter … A Casadei-Gardini, G Marisi, V Dadduzio, L Gramantieri, L Faloppi, P Ulivi, ... Clinical Cancer Research 26 (17), 4485-4493, 2020 | 16 | 2020 |
| Heavily calcified gastrointestinal stromal tumors: Pathophysiology and implications of a rare clinicopathologic entity M Salati, G Orsi, LR Bonetti, F Di Benedetto, G Longo, S Cascinu World Journal of Gastrointestinal Oncology 9 (3), 135, 2017 | 16 | 2017 |
| Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey G Orsi, M Di Marco, A Cavaliere, M Niger, S Bozzarelli, G Giordano, ... ESMO open 6 (5), 100238, 2021 | 14 | 2021 |
| Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib A Casadei-Gardini, V Dadduzio, G Rovesti, G Cabibbo, R Vukotic, ... Medicine 99 (22), e19958, 2020 | 13 | 2020 |
| The impact of nutritional status on pancreatic cancer therapy G Capurso, N Pecorelli, A Burini, G Orsi, D Palumbo, M Macchini, R Mele, ... Expert Review of Anticancer Therapy 22 (2), 155-167, 2022 | 12 | 2022 |
| Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma I Trestini, L Carbognin, U Peretti, I Sperduti, A Caldart, D Tregnago, ... Frontiers in Oncology 11, 688889, 2021 | 12 | 2021 |
